Showing 8 results for Hepatitis B
Baniaghil S, Sarafnejad A, Amirzargar A, Khosravi F, Ansaripour B, Moradi B, Dorkhosh S, Nikbin B,
Volume 64, Issue 11 (10-2006)
Abstract
Background: The outcome of acute hepatitis B infection may be influenced by host genetic factors like human leukocyte antigen (HLA). To investigate the association between the HLA-DRB, DQA1 and DQB1 alleles and chronic hepatitis B infection, 50 patients with chronic hepatitis B (based on 6 months positive of HBsAg and HBc antibody and HBeAg and antibody by serological test), were selected from Turkman population in north east of Iran .Allele frequency in patients were compared with a 65 aged and sex match control group from healthy blood donor of that ethnic population.
Methods: HLA DRB, DQA1 and DQB1 alleles were determined using polymerase chain reaction based on sequence specific primer (PCR-SSP) method. Allele frequencies in patients and control subjects were compared by Epi-info statistical soft-wear.
Results: There was a significant increase and positive association in HLA-DRB1*0301, DQA1*0501 and DQB1*0604 allele frequency in patients group while the frequency of HLA-DRB1*1301, 1501 and DQB1*0401 and DQA1*0401, 0102 were lower in patients than control group and shows negative association.
Conclusion: In Iranian Torkman population, HLA DRB1*0301, DQA1*0501 and DQB1*0604 have an important role in susceptibility to chronic hepatitis B infection and HLA DRB1*1301, 1501, DQB1*0401 are associated with protection to chronic hepatitis B infection. Larger case control studies may be helpful to confirm our investigation.
Fazeli Mr, Abbaspour M, Ghahremani Mh, Alimian M, Ilka H, Jamalifar H, Azadi S, Azizi E,
Volume 64, Issue 12 (11-2006)
Abstract
Background: Aluminum salts are common adjuvants in human and animal vaccine preparations. The two adjuvants aluminum phosphate and aluminum hydroxide show acceptable immunoadjuvant properties with many antigens. These two salts have different physicochemical characteristics that make each one suitable for certain antigens. The surface antigen of Hepatitis B (HBsAg) has several antigenic epitopes that bind to aluminum adjuvants by a ligand exchange mechanism. Although HBV vaccines using an aluminum hydroxide adjuvant are available, higher antigenicity is needed for the subgroup of people who do not respond sufficiently to the currently available vaccines.
Methods: A solution of recombinant HBsAg for making different formulations of vaccines with aluminum phosphate (Adju-Phos®) and aluminum hydroxide (Alhydrogel®) adjuvants was obtained from Darupakhsh Pharmaceutical Company. The total protein content, antigenicity, and purity of HBsAg solution were determined using BCA, ELISA, and SDS-PAGE methods, respectively. The different formulations were prepared in the lab and administered i.p. to two test groups of Balb/C mice and a third test group received the Engerix vaccine, which is currently available on the market and uses an aluminum hydroxide adjuvant. The control group of animals received the solution without antigen. After 28 days, heart blood samples were collected and serum was separated to determine the antibody titer against HBsAg using an ELISA kit.
Results: This study shows that the vaccine formulated with aluminum phosphate exerted more immunogenicity than both the aluminum hydroxide laboratory formulation and the Engerix vaccines.
Conclusion: Although the results of our study indicate higher immunogenic properties of the vaccine formulated with the aluminum phosphate adjuvant, complementary experiments are needed to further evaluate the biological properties with respect to effectiveness, adverse effects, product stability and finally possibility for manufacturing and distribution of this new formulation as a Hepatitis B vaccine.
Kazemi Arababadi M, Pourfathollah Aa, Jafarzadeh A, Hassanshahi Gh, Rezvani Me,
Volume 67, Issue 5 (8-2009)
Abstract
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4 Background: Occult hepatitis
B infection (OBI)
is a form of hepatitis in which despite absence of detectable HBsAg, HBV-DNA
is present in peripheral blood of patients. The responsible mechanisms for
progression of OBI yet to be clarified, but some investigators believed that the genetics and
immunological parameters are different in resistant individuals and patients.
Vitamin D3 and its receptor interaction
could be involved in anti-viral immune response. The aim of this study was to
investigate the association between polymorphisms in intron 8 of VDR with OBI.
Methods: In this experimental study, the plasma samples of 3700
blood donors were collected and tested for HBsAg and anti-HBs by ELISA.
The HBsAg negative and anti-HBc positive
samples were selected and screened for HBV-DNA
using PCR. HBV-DNA positive samples were assigned as OBI cases and PCR-RFLP
was performed to examine the polymorphisms in intron 8 of VDR genes.
Results: Results of current study indicated that 352 (9.5%)
of 3700 blood samples were HBsAg- and anti-HBc+. HBV-DNA
was detected in 57/352 (16.1%) of HBsAg- and anti-HBc+ samples.
Our results showed that no significant difference was observed in Apa-1 polymorphisms
of intron 8 of VDR and OBI patients.
Conclusion: Our results demonstrated
that there are not any association between Apa-1 detected alleles and OBI, hence, it can be concluded that these alleles are
not associated with OBI and other researchers
should evaluate relation between other polymorphisms of VDR with OBI.
Bahari A, Izadi Sh, Adibi P, Sanee-Moghadam E, Khosravi H, Shahraki T,
Volume 69, Issue 4 (7-2011)
Abstract
800x600 Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4
Background: With respect to the importance of hepatitis B
vaccination of high-risk groups such as prisoners, this study was performed to assess
the comparability of a short-course double-dose vaccination schedule with the
standard 3-dose schedule.
Methods : Within a randomized clinical trial, a short-course vaccination (at months 0
and 1) with 20
microgram (double-dose) doses of the vaccine was compared to the standard
method of hepatitis B vaccination (at
months 0, 1 and 6,
with 10-microgram doses) in 100
prisoners in Zahedan city in Iran in 2009.
We made sure the sera from all the individuals were negative for markers of
previous hepatitis B infection. Subsequently
serum from all the participants was tested for anti-HBs
antibody 1, 2 and 7
months after the first dose of vaccination.
Results : Seroconversion rates (HBsAb>10
mIU/ml) 1, 2
and 7 months after the first dose of vaccination
were similar in the routine (11%, 79% and 94%,
respectively) relative to the double-dose group (26%, 95% and
93 %, respectively). The mean values of anti-HBs
antibody titers were similar in the 1st and 2nd
months for the two groups but it was significantly higher (P=0.002)
in the routine dose (514 mIU/ml)
versus the double-dose group (130 mIU/mL),
in the 7th month.
Conclusion: Demonstrating
comparable results with the standard 3-dose
schedule, it seems that short-term double-dose vaccination for hepatitis B is
a safe and acceptable method for use in high-risk groups such as prisoners.
Jafar Mohammadshahi , Soheila Refahi , Bahareh Yousefipour , Mehran Sardari , Roghayeh Teimourpour ,
Volume 76, Issue 9 (12-2018)
Abstract
Hepatitis B virus (HBV) is an etiological agent of hepatitis B infection. Hepatitis B is a life-threatening disease that affects the liver. The clinical outcomes of the disease are varied from asymptomatic disease to serious complication such as cirrhosis and hepatocellular carcinoma (HCC). Despite availability of the vaccine and appropriate treatment, hepatitis B infection still remains a major public health problem worldwide. Based on WHO reports, over 887.000 people die annually from hepatitis B complication including cirrhosis and hepatocellular carcinoma. Hepatitis B is very contagious and spreads through infected blood, body fluids, mother to baby during birth, contaminated needle and between sexual partners. HBV uses sodium taurocholate cotransporting polypeptide (NTCP) receptor to enter hepatocytes and by replicating in these cells interferes with liver functions. In fact liver damage is as result of virus multiplication and activation of immune responses especially virus-specific cytotoxic T lymphocytes (CTLs) against infected cells. CTLs and CD4Th1 cells by killing infected cells and releasing antiviral cytokines control virus replication in infected individuals. Also, the functions of these cells in patients who successfully clear the infection are potentially strong. In contrast to acute self-limited HBV infection in persistent HBV infection, these cells are exhausted. Several studies have showed that the great challenge in clearance of the HBV infection is related to stability of covalently closed circular DNA (cccDNA). cccDNA produce in viral life cycle and remains inside the infected cells for a long time and act as a template for generating new pre-genomic RNA and virus propagation. So far, no antiviral treatment has been effective in the complete elimination of this structure. Prevention of the disease can be achieved by using effective vaccine. Previous studies indicated that neutralizing antibodies against surface antigen of the virus known as S antigen have protective properties. Therefore, a subunit vaccine containing S antigen is available. Currently S antigen is produced in recombinant form and WHO recommended the first dose should be given within a day of birth. Pegylated IFN-γ and nucleotide-nucleoside analogues are effective drugs against HBV infection, but they may have severe side effects. Ineffectiveness of the vaccine on premature infants and immunocompromised people and also drug side effects has made HBV infection a great trouble.
Mina Ghodsi Garamaleki , Changiz Ahmadizadeh ,
Volume 76, Issue 10 (1-2019)
Abstract
Background: Hepatitis B is the most common blood-borne viral infection that is considered as a major public health problem of the world's major health problems. The aim of this study was to investigate the prevalence of hepatitis B virus (HBV) infection among blood donors referring to blood transfusion centers.
Methods: This retrospective cross-sectional study was performed on 216004 volunteer blood donors referring to blood transfusion centers of Iran from the beginning of April 2011 to April 2015. Then the positive hepatitis B surface antigen (HBsAg) test was performed using the enzyme-linked immunosorbent assay (ELISA) and neutralization methods.
Results: Of the 216004 blood donors, 279 (12.12%) were positive for HBsAg, and the incidence of infection was a decreasing trend over a four-year period. Among HbsAg positive cases, 97.14% and 2.86% were male and female, respectively. Significant differences between males and females were found (P=0.000). The number of HBsAg positive cases among married people (238 cases, 85.3%) in compared with single people (41 cases, 14.7%) was significantly higher (P=0.000). The average age of HBV infected cases was 39.6±10.3 years. Most HBsAg positive cases were 45-36 years old (30.8%) and lowest prevalence was seen in the age group above 56 years old (4.6%). Highest infected people with Hepatitis B Virus had low degree of education. Relationships between HBV infection with age and degree of education were statistically significant (P=0.000).
Conclusion: The results of this study showed that based on our findings, prevalence of hepatitis B surface antigen among blood donors have declined significantly during the four years of study.
Mansour Bahardoust, Marjan Mokhtare , Arezoo Chaharmahali , Fatemeh Mousazadeh , Shahram Agah ,
Volume 77, Issue 3 (6-2019)
Abstract
Background: Psychosocial issues and quality of life are important components at the patients diagnosed with chronic hepatitis B and C. Hepatitis is a chronic liver disease that can affect quality of life of patients. In this study, we compared the quality of life between patients with hepatitis B and C and finally presented a structural model about it.
Methods: In a prospective analytic study, 86 patients with hepatitis B and 86 with hepatitis C who referred to the Rasoul-e-Akram Hospital in Tehran from April 2015 to April 2018 were compared regarding the quality of life and health-related quality of life. The clinical and radiographic data of patients were extracted from their medical records. The 36-item short-form health survey (SF-36) was used for the evaluation quality of life and health-related quality of life. The questionnaire consisted of 36 questions in eight sub-scales (physical performance, physical role, physical pain, general health, vitality, social role, emotional role, and mental health).
Results: Generally, the quality of life score was significantly lower in patients with hepatitis C (34.13±9.37) than patients with hepatitis B (51.5±10.5) (P=0.001). Except for the physical role and vitality, all other SF-36 subscales were significantly lower in the HCV patients group (P>0.05). Based on the results of logistic regression, the emotional dimension of patients was reported as most important effect on the quality of life in patients [(OR=9.15, 95% CI=(4.11-15.41), P=0.001)]. Based on the results of linear analysis, hepatitis type [(B=4.21, P=0.001)], patient income [(B=2.57, P=0.001)], the level of education [(B=2.9, P=0.014)] and the gender of patients [(B=2.77, P=0.023)] were reported as most important factors affecting the quality of life of patients, respectively. There was no significant difference between age, body mass index and smoking reported in patients' quality of life (P>0.05).
Conclusion: According to the results of this study, the quality of life in patients with hepatitis C was significantly lower than the quality of life in patients with hepatitis B.
Mansour Bahardoust, Marjan Mokhtare , Shahram Agah ,
Volume 77, Issue 5 (8-2019)
Abstract
Background: Hepatitis is among the major health problems, especially in developing countries. During past decades, the association between type of blood group (ABO) and hepatitis B and C virus has always been discussed. This study was designed to investigate the possible association between type of ABO blood group and chronic hepatitis B and C infection.
Methods: In the present analytical study, frequency of blood groups and their relationship with hepatitis B and C were evaluated in three groups: group A (patients with hepatitis B), group B (patients with hepatitis C) and group control (subjects with non-hepatitis B and C). The study was done from October 2016 to October 2018 on patients who referred to Rasool-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Demographic and laboratory data of all participants were extracted and collected from their medical records.
Results: Overall, 196 and 103 patients in group A, B and three hundred control were included in this study, respectively. The baseline demographic data of patients were not significantly different between treatment groups. The mean age of participants was 35.1±13 years. The O blood group was significantly higher in patients with hepatitis B (46.4%) and hepatitis C (41.9%) compared to control group (34%) (P=0.001). The risk of hepatitis B and C infection were significantly higher among patients with O blood group (OR = 3.9, 95% CI 2.1-5.9; P = 0.001) and (OR = 2.7, 95% CI 1.7-5.6; P = 0.02), respectively] while, the risk of hepatitis B infection was significantly lesser in participants with blood group A (OR = 0.4, 95% CI -1.2-0.8). Rh positive participants significantly were at higher risk of hepatitis (B and C) than Rh negative participants. (P<0.05).
Conclusion: Participants with blood group O were at higher risk for chronic hepatitis B and C B infection and antigen (Rh) positive. Hepatitis B infection was reported lesser in participants with blood group A.
